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Introduction: Alterations of serum metabolites may allow
us to identify individuals with lung cancer and advance our
understanding of the nature and treatment of their cancer.
We aimed to identify serum metabolites that differentiate
patients with lung cancer from at-risk controls.
Methods: Serum samples from patients with biopsy-
conﬁrmed untreated stage I through stage III non–small cell
lung cancer and at-risk controls were divided into fractions for
analysis by ultrahigh-performance liquid chromatography–
tandem mass spectrometry and gas chromatography–mass
spectrometry. Compounds were identiﬁed by comparison
with library entries of puriﬁed standards. Differences in con-
centrations of single metabolites and metabolite ratios were
identiﬁed. Prediction models were developed.
Results: Serum samples from 284 subjects was analyzed.
The subjects’ mean age was 67 and 48% were female.
Ninety-four patients had lung cancer (50 had adenocarci-
noma and 44 had squamous cell carcinoma), 44% had stage
I disease, 17% had stage II disease, and 39% had stage III
disease. The patients with cancer were slightly older than
the controls (68.7 versus 66.2 years, p ¼ 0.013). A total of
534 metabolites were identiﬁed in eight metabolite super-
pathways and 73 subpathways. The concentrations of 149
metabolites differed signiﬁcantly (q values <0.05) between
the cancer and control groups (70 were lower in the cancer
group and 79 were higher), and 9723 metabolite ratios
differed signiﬁcantly (q values <0.001) between the cancer
and control groups. The accuracies of the models (cancer
and cancer subtypes versus control) trained on 70% of the
subjects and tested on 30% (expressed as C-statistics)
ranged from 0.748 to 0.858.
Conclusions: Differences in the serum metabolite proﬁle
exist between patients with stage I through stage III
non–small cell lung cancer and matched controls.Journal of Thoracic Oncology Vol. 11 No. 1: 72-78 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
The pathogenesis of lung cancer involves a compli-
cated interplay between our natural defenses and the
effect of exposure to extrinsic insults capable of altering
the normal cellular life cycle. Uncorrected modiﬁcations in
cellular behavior can be identiﬁed as molecular changes
across the spectrum of systems biology. Alterations in
genetic, transcriptional, and proteomic function result in
changes in the metabolic properties of cancer cells. These
metabolic changes are reﬂected in the composition of
small molecule metabolites in cancer tissue, blood, and
urine. Knowledge of distinguishing patterns of small
molecule metabolites may allow us to identify individuals
with lung cancer, better understand the nature of their
cancer, and develop novel means of targeting the cancer.
Metabolite proﬁling is a relatively underrepresented
ﬁeld of biomarker development for identifying and
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identiﬁed as differences in the concentration of a single
metabolite or alterations of the constituents of an entire
metabolic pathway. Previous studies have identiﬁed
metabolite differences in the blood of patients with
non–small cell cancer that are related to altered amino
acid metabolism, glycolysis and gluconeogenesis, protein
metabolism, handling of oxidative stresses, and fatty
acid metabolism.1–12 Metabolite proﬁles have made it
possible to distinguish patients with lung cancer from
those without.1–12
Lung cancer is a heterogeneous disease that develops
in a heterogeneous population.13 The metabolic proﬁle
of each individual is somewhat unique, as is the meta-
bolic behavior of his or her cancer.14 This uniqueness
makes it difﬁcult to identify one distinct metabolic pro-
ﬁle of lung cancer. Global metabolite proﬁling may pro-
vide a broad overview of the potential metabolic
alterations, thereby allowing for reﬁnements in proﬁling
to occur on the basis of the phenotype of the patient and
the cancer. In this study, we used global metabolite
proﬁling of serum with the aim of identifying metabolic
characteristics that differentiated patients with stage I
through stage III primary lung adenocarcinoma and
squamous cell carcinoma from a phenotypically similar
group of patients without lung cancer. Some of the re-
sults of this study have been reported previously in the
form of an abstract.15
Materials and methods
The study protocol was approved by the Institu-
tional Review Board of the Cleveland Clinic (10-521).
All study subjects signed written informed consent.
Metabolomics proﬁling services were performed by
Metablon under contract with the Cleveland Clinic. The
Cleveland Clinic paid for these services and owns the
data presented. The results of metabolite proﬁling were
received by the Cleveland Clinic before Metabolon
received information about the category of the samples
(cancer or control). All statistical analyses presented in
the manuscript were performed by X. F. W. and Q. Z. of
the Cleveland Clinic.Study subjects
All samples from the subjects were obtained from a
lung cancer biorepository maintained by the Cleveland
Clinic. Study subjects were included in the biorepository
if they had biopsy-conﬁrmed untreated lung cancer or if
they were at risk for development of lung cancer on the
basis of an age older than 40 years and tobacco use of at
least 10 pack-years, a family history of lung cancer, or
the presence of chronic obstructive pulmonary disease.
Study subjects were excluded from the biorepository ifthey had a previous history of lung cancer, had a history
of another cancer within 5 years, were receiving im-
munosuppression, or were using continuous supple-
mental oxygen. For this study, all patients in the cancer
group had adenocarcinoma or squamous cell carcinoma
and stage I through stage III disease. Two control sub-
jects were selected for each patient with cancer through
propensity matching, with age, sex, smoking history,
presence or absence of diabetes, elevated cholesterol
level, and presence of chronic obstructive pulmonary
disease used for the matching. Data collection included
demographic variables and comorbidities for all sub-
jects, histologic diagnosis of cancer, stage, and survival
for the subjects in the cancer group. All blood samples
were drawn and stored at –80C as 500-mL aliquots
of serum until they were sent to Metabolon on dry
ice as batched, de-identiﬁed samples for testing. All
samples were maintained at Metabolon at –80C until
processed.Sample preparation
To remove protein, dissociate small molecules bound
to protein or trapped in the precipitated protein matrix,
and recover chemically diverse metabolites, the proteins
were precipitated with methanol by vigorous shaking
for 2 minutes (Glen Mills Inc., Clifton, NJ) as described
previously.16,17 The resultant extract was divided into
four fractions: one for analysis by ultrahigh-performance
liquid chromatography–tandem mass spectrometry
(UPLC-MS/MS) run in positive mode, one for analysis by
UPLC-MS/MS run in negative mode, one for analysis by
gas chromatography–mass spectrometry (GC/MS), and
one aliquot that was retained for backup analysis, if
needed.Mass spectrometry analysis
Nontargeted UPLC-MS/MS and GC/MS analyses
were performed at Metabolon, Inc., as described.16–18
The UPLC-MS/MS portion of the platform incorporates
a Waters Acquity UPLC system (Waters Corporation)
and a Thermo-Finnigan LTQ mass spectrometer (Thermo
Fisher Scientiﬁc Inc.), including an electrospray ioni-
zation source and linear ion-trap mass analyzer. Ali-
quots of the vacuum-dried sample were reconstituted,
one each in acidic or basic liquid chromatography–
compatible solvents containing eight or more injection
standards at ﬁxed concentrations (to ensure both in-
jection and chromatographic consistency). Extracts
were loaded onto columns (Waters UPLC BEH C18-2.1 x
100 mm, 1.7 mm, Waters Corporation) and gradient
eluted with water and 95% methanol containing 0.1%
formic acid (acidic extracts) or 6.5 mM ammonium
bicarbonate (basic extracts). The instrument was set to
74 Mazzone et al Journal of Thoracic Oncology Vol. 11 No. 1scan 99 to 1000 m/z and alternated between MS and
MS/MS scans.
Samples analyzed by GC/MS were dried under vac-
uum desiccation for a minimum of 18 hours before being
derivatized by using bis(trimethylsilyl)triﬂuoroacet-
amide as described.19 Derivatized samples were sepa-
rated on a 5% phenyldimethyl silicone column with
helium as the carrier gas and a temperature ramp from
60 to 340C within a 17-min period. All samples were
analyzed on a Thermo-Finnigan Trace DSQ fast-scanning
single-quadrupole mass spectrometer (Thermo Fisher
Scientiﬁc Inc.) operated at unit mass resolving power
with electron impact ionization and a scan range of 50
to 750 atomic mass units.Quality control
All the columns and reagents to complete all related
experiments were purchased in bulk from a single lot. For
monitoring of data quality and process variation, multiple
replicates of extracts from a pool of human plasma were
prepared in parallel and injected throughout the run,
interspersed among the experimental samples. Instru-
ment variability was determined by calculating the me-
dian relative standard deviation for the standards that
were added to each sample before injection into the mass
spectrometers (median relative standard deviation 6%).
Overall process variability was determined by calculating
the median relative standard deviation for all endoge-
nous metabolites (i.e., noninstrument standards) present
in 100% of the pooled human plasma samples (median
relative standard deviation 12%). In addition, process
blanks and other quality control samples were spaced
evenly among the injections for each day, and all exper-
imental samples were randomly distributed throughout
each day’s run.Compound identiﬁcation, quantiﬁcation,
and data curation
Metabolites were identiﬁed by automated comparison
of the ion features in the experimental samples to a
reference library of chemical standard entries that
included retention time, molecular weight, preferred
adducts, and in-source fragments as well as associated
MS spectra and curated by visual inspection for quality
control using software developed at Metabolon.20 Iden-
tiﬁcation of known chemical entities was based on
comparison with metabolomic library entries of more
than 3500 commercially available puriﬁed standards.
Peaks were quantiﬁed using area under the curve. Raw
area counts for each metabolite in each sample were
normalized to correct for variation resulting from inter-
day differences in instrument tuning by the median value
for each run-day, with the medians set to 1.0 for each run.Missing values were imputed with the observed mini-
mum after normalization.Statistical methods
Cancer cases were matched to controls (see earlier)
on the basis of the results of propensity score matching
using the greedy matching technique to reduce sample
selection bias. Demographic variables were described by
using sample mean with standard deviation or propor-
tion as appropriate. The study group was divided into
cancer and control groups. Categorical variables were
compared using the Pearson chi-square test, whereas
continuous variables were compared using the two-
sample independent t test.
Metabolite concentrations were returned to the
Cleveland Clinic as raw data and scaled data for analysis.
Missing values in the data set, which were generally due
to the metabolite level falling below the instrument’s
limit of detection, were imputed with the minimum
measured value of that metabolite to account for the
missing data. Statistical analyses were performed on
natural log-transformed data. Differences in metabolite
concentrations between the cancer and control groups,
as well as (separately) differences in ratios of metabolite
concentrations, were ﬁrst assessed with a univariate
robust t test for each metabolite using the method of
empirical Bayesian shrinkage of the standard errors,21
followed by the application of Benjamini and Hoch-
berg’s multiple comparison approach to determination
of the false discovery rate.22 This comparison was
performed ﬁrst for the entire group of subjects with
cancer and control subjects and then separately by his-
tologic diagnosis.
We built all the models presented by using the full
data sets and including all metabolites. Our procedure
for building the prediction model included two addi-
tional steps. First, a resample-based feature elimination
algorithm that incorporated correlation analysis was
conducted to select the important features and avoid
multicollinearity of model ﬁtting.23 Second, random
forest models were built using the selected variables to
predict cancer. Models were developed for all subjects
with lung cancer and all controls and then separately on
the basis of histologic diagnosis. Models were built using
the entire data set for each comparison and separately
on the basis of a training set of 70% of the subjects
with testing on the remaining 30%. This process was
repeated 100 times to avoid randomness of data split-
ting. Drugs and drug metabolites were excluded from
the model-building procedure (72 in total, 10 of which
differed between the cancer and control groups) and
from the metabolite ratio calculations. C-statistics were
calculated by the rank correlation between predicted
Table 2. Metabolite differences categorized by metabolite
superpathway
Superpathway Number Different Upa Downa
Amino acid 96 22 10 12
Peptide 30 12 5 7
Carbohydrate 25 4 3 1
Energy 9 0 0 0
Lipid 191 68 44 24
Nucleotide 22 5 4 1
Cofactors and vitamins 25 8 3 5
Xenobiotics 136 30 10 20
Total 534 149 79 70
aUp indicates a higher level in the patients with cancer than in the
controls, and down indicates a lower level in the patients with
cancer than in the controls.
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response.
We ﬁrst determined the accuracy of the model of
cancer versus control from differences in concentrations
of single metabolites and then reexamined the accuracy
using metabolite ratios to see whether a potential
substrate–product pairing or otherwise unknown meta-
bolite relationship might strengthen the model in com-
parison to individual metabolites. Ratios of normalized
concentrations of each single metabolite to all other
single metabolites, excluding xenobiotics, were used in
this analysis. All analyses were performed by using the
R statistical package (www.r-project.org). Additional
detail on the methods used in this study is provided in
the online data supplement.
Results
Serum samples from 284 subjects were analyzed.
Their mean age was 67 years, and 48% of them were
female. Ninety-four patients had lung cancer (50 had
adenocarcinoma and 44 had squamous cell carcinoma);
44% had stage I disease, 17% had stage II disease, and
39% had stage III disease. The patients with cancer were
slightly older than the controls (68.7 versus 66.2 years,
p ¼ 0.013); all other matched variables were not
signiﬁcantly different (Table 1).
A total of 534 metabolites were identiﬁed in eight
metabolite superpathways and 73 subpathways. After
correction for multiple comparisons (q < 0.05), the
concentration of 149 metabolites differed signiﬁcantly
between the cancer and control groups (70 lower in the
cancer group and 79 higher) (Table 2 and Supplementary
Tables 1 and 2). Sixty-ﬁve metabolite concentrations
differed signiﬁcantly between the subjects with adeno-
carcinoma and matched controls after adjustment
for multiple comparisons (q < 0.05), ﬁve of which were
unique (i.e., not different in the aforementioned com-
parison of all subjects with cancer and control subjects).Table 1. Demographics, comorbidities, and cancer
characteristics of the study cohort
Characteristic
Patients with
cancer (n ¼ 94)
Controls
(n ¼ 190)
p
Value
Age (y) 68.7 66.2 0.0125
Female sex (%) 44.7 49.5 0.4468
History of smoking (%) 95.7 97.4 0.4623
COPD (%) 29.8 23.7 0.2681
DM (%) 11.7 8.9 0.4637
Elevated lipid level (%) 21.3 19.5 0.7211
Adenocarcinoma (n) 50
Squamous cell (n) 44
Stage I (%) 44
COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus.Fifty metabolite concentrations differed signiﬁcantly be-
tween subjects with squamous cell carcinoma and
matched controls after adjustment for multiple compar-
isons (q < 0.05), including three that were unique. None
of the metabolite concentrations differed between sub-
jects with adenocarcinoma and squamous cell carcinoma
after adjustment for multiple comparisons. Of the 534
metabolites, 72 were classiﬁed as drugs or drug metab-
olites. Most of these metabolites were present in fewer
than 10% of the study subjects. Those present in greater
than 10% of study subjects included acetaminophen,
nonsteroidal antiinﬂammatory drugs, and their metabo-
lites. The concentration of 10 of the 72 differed between
the cancer and control groups; nine were elevated (eight
were acetaminophen and its metabolites), and one was
lower. Three lipid-lowering drugs were identiﬁed—none
in more 10% of study subjects and none with different
levels between the cancer group and the controls.
Metabolite ratios were evaluated separately. Of the
106,491 metabolite ratios (after correction for multiple
comparisons at q values less than 0.05, less than 0.01,
and less than 0.001, respectively), 34,680, 20,196, and
9723 differed between all subjects with cancer and
control subjects (the top 64 were used for model
building, see Supplementary Table 3); 17,985, 6648, and
1249 differed signiﬁcantly between subjects with
adenocarcinoma and matched controls the (top 57 were
used for model building); and 16,917, 5921, and 1390
differed signiﬁcantly between subjects with squamous
cell carcinoma and matched controls (the top 38 were
used for model building). No metabolite ratios differed
signiﬁcantly between subjects with adenocarcinoma and
squamous cell carcinoma after adjustment for multiple
comparisons.
Models using metabolite concentrations and separate
models using metabolite concentration ratios made it
possible to separate cancer groups from control groups.
The accuracies (expressed as C-statistics) of models built
Table 3. Accuracy of models of cancer versus control built from differences in concentrations of single metabolites and
metabolite concentration ratios
Type of cancer
Single-metabolite models Metabolite ratio models
Model
C-statistic
Model
OOB
Validation
C-statistic (CI)
Model
C-statistic
Model
OOB
Validation
C-statistic (CI)
Lung cancer 0.869 0.193 0.831 (0.823–0.840) 0.908 0.183 0.848 (0.839–0.858)
Adenocarcinoma 0.814 0.211 0.748 (0.734–0.761) 0.938 0.165 0.753 (0.739–0.768)
Squamous cell carcinoma 0.926 0.144 0.839 (0.827–0.850) 0.955 0.121 0.858 (0.844–0.873)
OOB, out of bootstrap; CI, conﬁdence interval.
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whereas the validated accuracies of models trained on
70% of the subjects and tested on 30% ranged from
0.748 to 0.858 (Table 3). The single-metabolite models
included 20 metabolites each (Table 4).Discussion
We report the results of global small molecule
metabolite proﬁling of the serum of patients with stage I
through stage III adenocarcinoma and squamous cell
carcinoma. Metabolite concentrations and ratios of
metabolite concentrations in the patients with cancer
were compared with those of controls who were matched
for demographic and comorbidity characteristics that
could alter their metabolite proﬁle. We identiﬁed 149
metabolites that were present in different concentrations
in the subjects with lung cancer. Metabolite differences
were identiﬁed across multiple metabolite superpath-
ways. Models developed on the basis of these differences
made it possible to separate subjects with lung cancer
from control subjects with good accuracy.
Several previous studies have evaluated blood
metabolite proﬁles of patients with lung cancer.1–12 The
studies have differed in terms of the breadth of metabo-
lite proﬁling (a single superpathway versus global
proﬁling), the proﬁling methodology used, and the
populations studied. These studies have suggested
differences in amino acid metabolism, glycolysis and
gluconeogenesis, protein metabolism, handling of oxida-
tive stresses, and fatty acid metabolism in the population
with lung cancer. Our study supports the presence of
these global alterations in metabolism. In addition, our
results suggest that in those with lung cancer, phenolic
compounds are reduced and activity of the trans-
sulfuration pathway is increased.
Although our results globally support what has been
reported in the literature, the speciﬁc metabolite alter-
ations identiﬁed in our study are different from those
identiﬁed by other investigators. Some of the differences
in metabolite concentration we report (e.g., for histidineand tryptophan) are concordant with previous reports, a
few (e.g., for sarcosine) are discordant, others have
variable results in the literature (high in one report and
low in another), and several metabolites that have
previously been reported to be present in different
concentrations in patients with lung cancer were not
different in our study.1–12 Most of the speciﬁc metabolite
differences that we report have not appeared in other
studies. This could be due to differences in study
methodology and the populations studied, or it could
simply reﬂect a lack of depth of analysis of the route
metabolite pathway alterations in the current study.
Further analysis of route metabolite pathway alterations
may tie together the ﬁndings of the current and previous
studies. No previous lung cancer study has evaluated
differences in the ratios of metabolite concentrations.
A deeper understanding of the metabolic pathways
that are altered to produce the concentration differences
that we have identiﬁed would help in validating and
applying our ﬁndings. An atlas of genetic inﬂuences on
human blood metabolites has been developed.24 Thirty
of the 149 metabolites whose concentrations differed
between patients with lung cancer and the controls
in our study have been connected with the potential
inﬂuence of a single nucleotide polymorphism.24 In our
review of the literature, none of these 30 single-
nucleotide polymorphisms have been reported to be
associated with lung cancer.
Our study has several strengths. We narrowed our
population of patients with cancer to those with stage I
through stage III adenocarcinoma and squamous cell
carcinoma, thus minimizing the inﬂuence of lung cancer
heterogeneity and advanced disease on the results. We
used propensity matching to identify controls whose
demographics and comorbidities were similar to those of
the subjects with lung cancer, which minimized these
inﬂuences on the metabolite proﬁles. We used techni-
cally validated methodologies that incorporate extensive
quality controls. We used conservative statistical anal-
ysis techniques, were careful to control for the mul-
tiple comparisons in this large data set, and analyzed
Table 4. Metabolites within the models of single metabolites
Cancer vs. control Adenocarcinoma vs. control Squamous cell vs. control
Arachidonate Arachidonate Pelargonate
Phosphate Phosphate Methionine
Pelargonate Pelargonate N1-Methyladenosine
Tyrosine Taurodeoxycholate N-Acetylmethionine
Methionine Nonadecanoate N-Acetylneuraminate
Nonadecanoate Cortisol Ascorbate
Inositol 1-phosphate Quinate Azelate
a-Tocopherol Theobromine Hypoxanthine
Hippurate Glycocholate Cysteine
N-Acetylalanine Stearoyl sphingomyelin N-(2-Furoyl)glycine
N-Acetylmethionine 2-Hydroxybutyrate DSGEGDFXAEGGGVR
N-Acetylneuraminate 3-Methyl-2-oxobutyrate Acetylcarnitine
Ascorbate 1,6-Anhydroglucose Hexanoylcarnitine
Cortisol 3-Hydroxydecanoate Alanine
2-Hydroxystearate Palmitoylcarnitine d-Tocopherol
Paraxanthine Hypoxanthine g-Tocopherol
Riboﬂavin Cysteine Eicosenoate
Quinate N-(2-Furoyl)glycine ADpSGEGDFXAEGGGVR
Azelate Acetylcarnitine 1-Methylxanthine
Theobromine Glycochenodeoxycholate Laurylcarnitine
January 2016 Metabolite Proﬁles of the Serum 77metabolite ratios separately, thereby highlighting the
interdependence of metabolites. Weaknesses of our
study include an incomplete ability to connect the
metabolite differences to speciﬁc deﬁned metabolic
pathways and validate our ﬁndings in separate patient
cohorts. This fact is particularly important because lack
of external validation of metabolite ﬁndings has been a
concern of metabolomics research. Not all potential in-
ﬂuences on the metabolite proﬁles (e.g., obesity) could
be controlled for. Addressing these weaknesses is a goal
for the future.
In conclusion, differences in serum metabolite pro-
ﬁles exist between patients with stage I through stage III
non–small cell carcinoma and matched controls. A
deeper understanding of these differences could provide
us with insight into the pathobiology of lung cancer, lead
to the development of novel lung cancer biomarkers, and
identify new targets for therapy.Acknowledgments
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